Know Cancer

or
forgot password

Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)


Phase 2
21 Years
N/A
Open (Enrolling)
Both
Bone Metastases

Thank you

Trial Information

Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)


Inclusion Criteria:



- Painful bone metastasis of solid tumors

- A maximum number of bone metastases less or equal to 3

- Life expectancy > 6 months

- Minimum age 21 years

- Signed informed consent

Exclusion Criteria:

- Previous radiotherapy to the painful site

- Bone metastasis from malignant melanoma or renal cell carcinoma

- Associated fracture or extra-osseous component

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Pain assessment

Outcome Time Frame:

t0

Safety Issue:

No

Principal Investigator

Wilfried De Neve, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Hospital, Ghent

Authority:

Belgium: Institutional Review Board

Study ID:

2006/098

NCT ID:

NCT00503178

Start Date:

April 2006

Completion Date:

July 2013

Related Keywords:

  • Bone Metastases
  • Neoplasm Metastasis
  • Neoplasms, Second Primary
  • Bone Neoplasms
  • Bone Marrow Diseases

Name

Location